Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
終値時点
$27.86
+$0.19 · +0.69%
時間外
$27.99
+$0.13 · +0.47%
10月13日 16:19 ET
日中の時刻はETです。市場データは遅延する場合があります。
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
日中レンジ
現在 $27.86
52週レンジ
現在 $27.86
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
88
大幅な割安
センチメント
58
まちまち
リスク
32
中程度のリスク
モメンタム
45
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
日中レンジ
現在 $27.86
52週レンジ
現在 $27.86
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 61.64億 USD | 58.1億 USD | 55.49億 USD | 52.15億 USD | 52.12億 USD |
| 売上原価 | 19.57億 USD | 17.31億 USD | 16.54億 USD | 15.15億 USD | 15.14億 USD |
| 粗利益 | 42.07億 USD | 40.79億 USD | 38.95億 USD | 37億 USD | 36.98億 USD |
| 研究開発 | 3.46億 USD | 3.43億 USD | 3.39億 USD | 3.45億 USD | 3.56億 USD |
| 販売・一般管理 | 30.36億 USD | 29.04億 USD | 28.34億 USD | 27.07億 USD | 26.37億 USD |
| 営業費用 | 34.13億 USD | 34.22億 USD | 34.7億 USD | 32.5億 USD | 31.05億 USD |
| 受取利息 | 2806.54万 USD | 2401.01万 USD | 3413.18万 USD | 1399.14万 USD | 599.93万 USD |
| 支払利息 | 1.41億 USD | 1.5億 USD | 1.33億 USD | 7995.06万 USD | 7999.05万 USD |
| 減価償却費と償却費 | 5.73億 USD | 5.55億 USD | 5.27億 USD | 5.48億 USD | 5.63億 USD |
| 営業利益 | 7.94億 USD | 6.57億 USD | 4.25億 USD | 4.5億 USD | 5.93億 USD |
| 純利益 | 6.25億 USD | 4.12億 USD | 2.63億 USD | 2.23億 USD | 5.24億 USD |
会社概要が更新されました 2026年10月13日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$31.91
上昇余地(14.54%)この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Total International Stock ETFVXUS1071.02万0.00%6657億 USD0.05%$84.54+0.12%
Vanguard FTSE Emerging Markets ETFVWO1045.3万0.01%1685億 USD0.06%$59.68-0.08%
Dimensional - International Core Equity 2 ETFDFIC823.63万0.05%150.91億 USD0.22%$37.68+0.56%
Avantis International Equity ETFAVDE753.79万0.04%192.5億 USD0.23%$90.05+0.52%
Dimensional World ex U.S. Core Equity 2 ETFDFAX501.09万0.04%123.22億 USD0.28%$37.00+0.22%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP222.81万0.08%26.34億 USD0.20%$65.01-0.38%
Vanguard FTSE All-World ex-US ETFVEU171.93万0.00%986億 USD0.04%$82.61+0.15%
Vanguard International High Dividend Yield ETFVYMI85.89万0.00%228億 USD0.07%$101.52+0.71%
Vanguard Total International Stock ETFVXUS
Vanguard FTSE Emerging Markets ETFVWO
Dimensional - International Core Equity 2 ETFDFIC
Avantis International Equity ETFAVDE
Dimensional World ex U.S. Core Equity 2 ETFDFAX
State Street SPDR S&P Kensho New Economies Composite ETFKOMP
Vanguard FTSE All-World ex-US ETFVEU
Vanguard International High Dividend Yield ETFVYMIAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。